If you've spent any time in mitochondrial health research, you've probably seen Urolithin A, SS-31 (also called elamipretide), and MOTS-c mentioned in the same breath. They get lumped together because they all touch the same organelle, the mitochondria, the structures inside your cells that turn food into usable energy. But "they're all mitochondrial" is about as useful as saying three people all "work in healthcare." The jobs are genuinely different, and that difference matters for how you'd sequence them.
What each one actually does
Urolithin A is a compound your gut bacteria produce when you eat certain foods (pomegranates and walnuts are the usual examples), though most people don't make enough of it on their own for research-relevant amounts. It's studied for a process called mitophagy, your cells' way of clearing out damaged mitochondria so they can be recycled or replaced. Think of it as quality control for your cellular power plants. It's taken orally, has GRAS (generally recognized as safe) status, and has one of the cleaner safety records of the three because it's been through actual human trials, not just cell and animal studies.
SS-31, also known as elamipretide, works differently. Instead of clearing out damaged mitochondria, it's studied for stabilizing the membranes of the mitochondria you already have, the equivalent of a tune-up rather than a replacement. It's an injectable research peptide with a meaningful amount of human trial data behind it and, anecdotally, a faster subjective readout than the other two.
MOTS-c is a mitochondrial-derived peptide studied mainly for metabolic signaling, meaning how your body manages glucose uptake and fat oxidation. Its strongest research base is around preventing insulin resistance and unwanted fat gain, which makes it a fundamentally different tool than the other two. It's not clearing anything or stabilizing anything; it's more like a dispatcher sending signals about how fuel gets used.
Clear the damaged ones, stabilize what's left, signal how fuel gets used. On paper, that's a genuinely sensible division of labor.
Why "additive on paper" doesn't mean "start together"
Here's the catch. Nobody has run all three together in a human trial, and each one individually has a modest effect size. That combination, unstudied together and individually subtle, means that if you start all three in the same window, you have no real way to know which one (if any) is responsible for anything you notice. You'd be spending money on three variables to arrive at a result you can't interpret.
That's not a safety statement. It's an attribution problem. If something in your research protocol is already titrating up or shifting phases, whether that's a GLP-1 dose increase or a repair peptide moving from loading into maintenance, adding a third or fourth moving variable on top of it makes the whole month unreadable.
A sequencing approach worth considering
If you're looking at all three eventually, researchers commonly reason through it in this order:
- Urolithin A first. It's oral, doesn't take up an injection slot, and has the cleanest safety file of the three. The typical study dose researchers reference is 500 mg per day taken with food, and the trials generally ran around four months, so it's realistic to expect it needs eight to twelve weeks minimum before there's anything meaningful to notice. This is a background compound, not an event.
- SS-31 second. It has the most human trial data of the three and, by most accounts, the fastest subjective readout, which makes it a better second variable to introduce once the first one is settled and isn't overlapping with anything else that's actively changing.
- MOTS-c last, and worth questioning whether you need it at all. Its strongest evidence is specifically around insulin resistance and fat gain. If your own metabolic picture, fasting insulin and HbA1c in particular, is already in a healthy range, you may not have the specific problem MOTS-c is best studied for solving. That's worth checking before adding it, not after.
The metabolic check worth doing before you start
Because MOTS-c's case rests on insulin and fat metabolism, fasting insulin and HbA1c, a blood test that reflects your average blood sugar over roughly the past three months, are the two markers that actually tell you whether it fits your situation. IGF-1 (insulin-like growth factor 1) is a different marker entirely, more relevant to research on compounds that prompt the body's own growth hormone release, and it doesn't move with any of these three compounds.
If you want objective evidence that Urolithin A or SS-31 did something, rather than relying entirely on how you feel, hs-CRP (a general inflammation marker) is worth drawing before you start anything. It's the single marker most likely to shift with a mitochondrial-focused compound, and it's only useful as a before-and-after comparison, so the "before" draw has to happen first. ApoB, a lipid marker some researchers consider more informative than standard cholesterol testing, is another cheap add-on to the same blood draw, though it's not specifically decision-relevant here.
Buying it well
Urolithin A is the outlier of the three here. It's not a peptide, it doesn't need reconstitution, and it doesn't require a research-vendor account, it's sold as a standard oral supplement. Timeline's Mitopure is the branded form most of the actual human trials referenced above were run on, which makes it a reasonable default if you'd rather not sort through vendor listings yourself. See it on Amazon.
SS-31 and MOTS-c are a different story. Both show up from a wide range of research suppliers, and price per mg varies more than people expect. Compare current pricing across vendors in our app before you buy either one, and treat third-party lab testing as non-negotiable regardless of how a listing is worded.
Where to go from here
If you're still deciding whether any of this fits your own research plan, finding quality sources covers what to look for in a vendor before you spend anything, and researching peptides on your own is a good next stop for building out a broader research approach beyond any single compound.
When you're ready to compare current per-mg pricing across vendors, the pricing tool pulls live numbers rather than relying on a listed retail price.
All content on Peptide Price Lab is for informational and research purposes only. Nothing here constitutes medical advice, and these compounds are not intended for human use. Always consult a licensed healthcare provider.